Nextdoor launches neighborhood-level ad targeting platform

Nextdoor Holdings (NXDR) reported Q2 2026 revenue of $75 million, up 15% year over year, and above guidance of $71 million to $73 million. Platform WAU rose to 22.9 million. Adjusted EBITDA was $10 million, with 13% margin. The company raised full-year revenue and adjusted EBITDA outlook and said it had $378 million cash and zero debt as of June 30, 2026.

Nextdoor Holdings, Inc. (NXDR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nextdoor Reports Second Quarter 2026 Results Delivered Q2 Results Ahead of Guidance Drove Second Consecutive Quarter of Sequential Platform WAU Growth Achieved Quarterly All-Time-High Platform WAU and Revenue Raises Full-Year 2026 Guidance SAN FRANCISCO, CA, August 4

Nextdoor Holdings (NYSE:NXDR) rose 9.7% to $2.2150 on Thursday, after closing at $2.02; it traded as high as $2.24 on volume of 1.41M shares, down 60% from average. Analysts cited mixed views: Citigroup cut its target to $2.10 (neutral) and Goldman set $2.25 (neutral). In its May 6 quarter, Nextdoor reported -$0.03 EPS vs -$0.05 consensus on $61.67M revenue.

NVIDIA released Nemotron 3.5 Super VL, a 120-billion-parameter model, on October 15, offering open weights and datasets. On October 21, NVIDIA and the German government formalized an AI ecosystem partnership, focusing on infrastructure. The model is adopted by companies like Scale AI and Salesforce, aiming to drive enterprise adoption and infrastructure demand. NVIDIA's strategy involves giving away the model to capture value through hardware and infrastructure.

GM unveiled a fourth-generation EV platform with 15% lighter vehicles, 20% more efficiency, and 20% less battery capacity. The platform uses lithium-manganese-rich (LMR) batteries, reducing costs. GM aims to launch vehicles on this platform shortly, targeting high-volume segments like crossover SUVs. The new architecture also features 30% less wiring and 40 times more processing power. The 2028 Cadillac Escalade IQ will be the first model with this technology.

Amgen (AMGN) reported 10% revenue growth in Q2, with Tezspire sales up 42%. However, earnings per share rose just 4%, raising questions about earnings growth. The company's newer drugs, like Repatha and Imdelltra, drove growth, but older drugs face biosimilar competition. MariTide, an obesity drug, is a key focus for future earnings.